Skip to content
DraconiticResearch
Search Sources API
174,684 studies31 sourcesUpdated 54 min ago
Peer-reviewedCC BY 4.0Cells

The Impact of the Antidiabetic Agent Sitagliptin on the Radiation Response of Breast Carcinoma Cells with Different Metastatic Capacities

  • Marie Theres Eling1,2,3
  • Anouk Bottema1,2,3
  • Dragana Savic1,2,3
  • Sergej Skvortsov1
  • Ute Ganswindt1
  • Petra Obexer4
  • Ira Ida Skvortsova1,2,3
4 affiliations
  1. 1Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria
  2. 2Laboratory for Experimental and Translational Research on Radio-Oncology (EXTRO-Lab), Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria
  3. 3Tyrolean Cancer Research Institute, 6020 Innsbruck, Austria
  4. 4Department of Pediatrics II, Medical University of Innsbruck, 6020 Innsbruck, Austria
Read full textPDFDOICite

Abstract

Breast cancer (BC) and type 2 diabetes mellitus (T2DM) often co-occur and can contribute to poorer clinical outcomes after therapy compared to non-diabetic cases. It is assumed that glucose-lowering drugs like DPP4 inhibitors (DPP4-Is), e.g., sitagliptin, can affect the radiation responses of BC cells. In this study, parental and invasive (INV) MDA-MB-231 (triple-negative BC) and T47D (luminal A) cells were used. INV cells revealed a significant upregulation of DPP4/CD26 molecules compared to their parental counterparts. All investigated cells were treated with sitagliptin, ionizing radiation, or both. It was found that the specific inhibition of DPP4/CD26 molecules using sitagliptin can protect triple-negative BC cells from cytotoxic ionizing radiation or improve the radiation response in luminal A BC cells independently of their metastatic abilities. The protective and sensitizing effects of sitagliptin do not depend on the level of senescence and/or autophagy initiation after treatment.

Related

  1. Prognostic value of the preoperative C-reactive protein-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma
    Minchao Qin, Zhongwen Feng, Chao Zhang +3
    PLOS OnePeer-reviewedCC BYFull textGeneral biochemistryCell biologyPLOSEurope PMCPMC
  2. Harnessing chia seed polysaccharides for green synthesis of copper-based nanoparticles with antidiabetic and anti-inflammatory activities
    Farzana Khan, Yusra Jamil, Raeesa Wajid +9
    PLOS OnePeer-reviewedCC BYFull textGeneral biochemistryCell biologyPLOSEurope PMCPMC
  3. Computational redesign of Chlamydomonas reinhardtii photosynthetic fructose-1,6-bisphosphatase from the Calvin-Benson-Bassham cycle improves both stability and catalytic capacities in vitro
    C. Quel Pinol, T. Chenuel, J. Henri
    bioRxivPreprintCC BYFull textMolecular biology & gene regulationbioRxiv
  4. Anatomical Heterogeneity in Longitudinal CA15-3 and CEA Rises Preceding Metastatic Breast Cancer Progression
    Zsanett Szilvási, Borbála Bruszniczky, János Tibor Fekete
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  5. Gut-liver axis in liver pre-metastatic niche formation: immune networks, microbial, and metabolic and emerging therapeutic opportunities
    Leyi Zhao, Qiutong Lin, Danyuan Zhang +8
    Frontiers in MicrobiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{eling2026impact,
  title = {{The Impact of the Antidiabetic Agent Sitagliptin on the Radiation Response of Breast Carcinoma Cells with Different Metastatic Capacities}},
  author = {Marie Theres Eling and Anouk Bottema and Dragana Savic and Sergej Skvortsov and Ute Ganswindt and Petra Obexer and Ira Ida Skvortsova},
  journal = {Cells},
  year = {2026},
  month = oct,
  doi = {10.3390/cells15201879},
  url = {https://www.mdpi.com/2073-4409/15/20/1879},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The Impact of the Antidiabetic Agent Sitagliptin on the Radiation Response of Breast Carcinoma Cells with Different Metastatic Capacities
AU  - Marie Theres Eling
AU  - Anouk Bottema
AU  - Dragana Savic
AU  - Sergej Skvortsov
AU  - Ute Ganswindt
AU  - Petra Obexer
AU  - Ira Ida Skvortsova
PY  - 2026
DA  - 2026/10/15
JO  - Cells
DO  - 10.3390/cells15201879
UR  - https://www.mdpi.com/2073-4409/15/20/1879
AB  - Breast cancer (BC) and type 2 diabetes mellitus (T2DM) often co-occur and can contribute to poorer clinical outcomes after therapy compared to non-diabetic cases. It is assumed that glucose-lowering drugs like DPP4 inhibitors (DPP4-Is), e.g., sitagliptin, can affect the radiation responses of BC cells. In this study, parental and invasive (INV) MDA-MB-231 (triple-negative BC) and T47D (luminal A) cells were used. INV cells revealed a significant upregulation of DPP4/CD26 molecules compared to their parental counterparts. All investigated cells were treated with sitagliptin, ionizing radiation, or both. It was found that the specific inhibition of DPP4/CD26 molecules using sitagliptin can protect triple-negative BC cells from cytotoxic ionizing radiation or improve the radiation response in luminal A BC cells independently of their metastatic abilities. The protective and sensitizing effects of sitagliptin do not depend on the level of senescence and/or autophagy initiation after treatment.
SN  - 2073-4409
ER  -